One-year treatment cost of dalbertam/pemetinib

Pemigatinib/Pemigatinib has an indication approved in many countries for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) with fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement. Pemetinib is a molecular kinase inhibitor with anti-tumor activity that inhibits fibroblast growth factor receptor (FGFR). FGFR is a receptor tyrosine kinase that activates signaling pathways in tumor cells. Pemetinib is a selective, potent oral inhibitor of FGFR 1, 2, and 3. Oral pemetinib is available in 4.5mg, 9mg and 13.5mg tablets. The recommended starting dose is 13.5 mg orally once daily for 14 days, followed by 7 days off treatment in a 21-day cycle.

Pemetinib tablets, the original drug of pemetinib, have been launched in the domestic market, but have not yet entered the medical insurance catalog. The currently sold pharmaceutical specifications include 4.5mg*14 tablets and 9mg*14 tablets. The price ranges from RMB 20,000 to RMB 50,000 per box, and the cost of treatment for one year may be as high as hundreds of thousands of RMB. At the same time, the price of the original pemetinib drug overseas is even higher. Taking 13.5 mg 14 tablets as an example, the price per box may be as high as more than 70,000 yuan (the price may change due to exchange rate fluctuations).

However, thankfully, generic drugs of pemetinib have appeared in overseas markets, and their ingredients are basically the same as the original drugs sold at home and abroad. For example, the 4.5mg 14-piece drug produced by Lucius Pharmaceuticals in Laos is priced at just over RMB 800 per box (the price may fluctuate due to exchange rates). Compared with the original drug, the cost for patients to use it for one year is greatly reduced. However, this is only a rough estimate and actual costs may vary depending on the patient's specific condition and medication regimen.